Temsirolimus repressed tumor growth more effectively than erlotinib (an EGFR inhibitor) in nude mice bearing xenografts derived from Detroit 562 cells (intermediate susceptibility to erlotinib), indicating that temsirolimus has potential as a therapeutic agent for EGFR-resistant head and neck cancer [43]. The gene discussed is EGFR; the disease is neoplasm.